GlassScriptPhysician profile
Saba Azher Ansari
NPI 1972506855
$1,459.60
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $40.52 · 2021: $395 · 2022: $680 · 2023: $43.41 · 2024: $17.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $60.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $60.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $184.19 | 2019-2024 | Arexvy, Shingrix |
| Abbvie INC. | $148.75 | 2021-2023 | Vraylar |
| Lilly USA, LLC | $127.39 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $113.39 | 2021-2022 | |
| Amgen INC. | $84.61 | 2019 | |
| Novo Nordisk INC | $80.58 | 2021-2022 | |
| Abbott Laboratories | $72.52 | 2022-2023 | Freestyle Libre 2 |
| Amarin Pharma, INC. | $72.28 | 2021-2022 | |
| Akcea Therapeutics, INC. | $71.88 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $44.72 | 2021 | |
| Sanofi-Aventis U.S. LLC | $44.13 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $40.78 | 2020-2022 | |
| Daiichi Sankyo INC. | $37.11 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.51 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $30.10 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $28.52 | 2020 | |
| Merck Sharp & Dohme LLC | $26.04 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $25.42 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.28 | 2021-2022 | |
| Urovant Sciences INC | $24.94 | 2022 | |
| Horizon Therapeutics Plc | $21.71 | 2021 | |
| Almatica Pharma LLC | $19.78 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.77 | 2022 | |
| Corium, LLC | $17.76 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.76 | 2022 | |
| Renalytix Ai, INC. | $14.90 | 2022 | |
| Sunovion Pharmaceuticals INC. | $14.85 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.69 | 2021 | |
| Eisai INC. | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saba Ansari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.